Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial

This prospective phase II study evaluated the efficacy of azacitidine (Aza)+erythropoietin (Epo) in transfusion-dependent patients with lower-risk myelodysplastic syndrome (MDS). Patients ineligible for or refractory to full-dose Epo+granulocyte colony stimulation factors for >8 weeks and a trans...

Descripción completa

Detalles Bibliográficos
Autores principales: Tobiasson, M, Dybedahl, I, Holm, M S, Karimi, M, Brandefors, L, Garelius, H, Grövdal, M, Högh-Dufva, I, Grønbæk, K, Jansson, M, Marcher, C, Nilsson, L, Kittang, A O, Porwit, A, Saft, L, Möllgård, L, Hellström-Lindberg, E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3972706/
https://www.ncbi.nlm.nih.gov/pubmed/24608733
http://dx.doi.org/10.1038/bcj.2014.8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3972706/
https://www.ncbi.nlm.nih.gov/pubmed/24608733
http://dx.doi.org/10.1038/bcj.2014.8

Ejemplares similares